European Fusion Development Agreement

Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIVO

Retrieved on: 
Tuesday, February 22, 2022
GLOBE, TSX, BRD4, Prostate cancer, Therapy, NCI, Disorder, TNBC, Zenith, Neoplasm, University, University of Pittsburgh Medical Center, MCRPC, National, University of California, San Francisco, Breast cancer, Safety, Nivolumab, BMS, European Fusion Development Agreement, MYC, Pfizer, Biotechnology, BET, Ipilimumab, Cancer, Patient, National Cancer Institute, PARP, Merck, Astellas Pharma, CEO, CTLA4, Ovarian cancer, Pembrolizumab, Pharmaceutical industry, Medical imaging

CALGARY, Alberta, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (Zenith or the Company) announced today the dosing of a first patient with a combination of ZEN-3694 (BET inhibitor) + Bristol Myers Squibbs PD-1 immune checkpoint inhibitor OPDIVO and YERVOY, in a National Cancer Institute (NCI), part of the National Institutes of Health, sponsored trial in solid tumor cancer.

Key Points: 
  • CALGARY, Alberta, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (Zenith or the Company) announced today the dosing of a first patient with a combination of ZEN-3694 (BET inhibitor) + Bristol Myers Squibbs PD-1 immune checkpoint inhibitor OPDIVO and YERVOY, in a National Cancer Institute (NCI), part of the National Institutes of Health, sponsored trial in solid tumor cancer.
  • This Phase 1/1b clinical trial will also evaluate a triple combination of ZEN-3694 + OPDIVO + YERVOY (an inhibitor of another immune checkpoints, CTLA4).
  • Upon determination of a dosing regimen of the aforementioned double and triple combination, the trial will be expanded to ovarian cancer patients who have progressed on platinum-based chemotherapy.
  • We have shown preclinically that BET inhibitors enhance the activity of checkpoint inhibitors by improving the tumor immune microenvironment.

NCI-Sponsored Trial of Uproleselan in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Completes Enrollment of Phase 2 Portion Ahead of Schedule

Retrieved on: 
Monday, December 6, 2021
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Patient, National, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Data, Cell, Cancer, Risk, Inflammation, Breakthrough therapy, NIH, EFS, Forward-looking statement, Hospital, AML, Carbohydrate, Acute myeloid leukemia, George Washington University School of Medicine & Health Sciences, SEC, National Cancer Institute, Annual report, European Fusion Development Agreement, Alliance for Clinical Trials in Oncology, Cooperative research and development agreement, U.S. Securities and Exchange Commission, Nasdaq, Washington University School of Medicine, Survival, Adult, Discovery (observation), E-selectin, Bone marrow, Principal investigator, NCI, Form 10-K, Multimedia, Food, Chemistry, Pharmaceutical industry, Uproleselan, GlycoMimetics, Inc., Alliance for Clinical Trials in Oncology, UPROLESELAN, GLYCOMIMETICS, INC., ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY

The randomized, controlled trial is evaluating the addition of uproleselan, GlycoMimetics investigational, first-in-class, targeted antagonist of E-selectin, to a standard cytarabine/daunorubicin regimen (7&3) in older adults with previously untreated AML who are suitable for intensive chemotherapy.

Key Points: 
  • The randomized, controlled trial is evaluating the addition of uproleselan, GlycoMimetics investigational, first-in-class, targeted antagonist of E-selectin, to a standard cytarabine/daunorubicin regimen (7&3) in older adults with previously untreated AML who are suitable for intensive chemotherapy.
  • Geoffrey Uy, M.D., Professor of Medicine, Washington University School of Medicine in St. Louis, is the trials Principal Investigator.
  • GlycoMimetics and NCI are collaborating on the development of uproleselan under a Cooperative Research and Development Agreement.
  • Together, the GlycoMimetics- and NCI-sponsored programs will constitute a large dataset of 650 patients with AML.

Fusion energy: Council approves ITER financing

Retrieved on: 
Tuesday, February 23, 2021
Tokamaks, European Atomic Energy Community, Fusion for Energy, ITER, DEMOnstration Power Station, Articles, Fusion power, Continents, Energy, European Fusion Development Agreement, Culham Centre for Fusion Energy

The Council today adopted a Decision securing the continuation of the European financing of the International Thermonuclear Experimental Reactor (ITER) project during the Multiannual Financial Framework (MFF) period 2021-2027.

Key Points: 
  • The Council today adopted a Decision securing the continuation of the European financing of the International Thermonuclear Experimental Reactor (ITER) project during the Multiannual Financial Framework (MFF) period 2021-2027.
  • Next steps

    The Council Decision shall enter into force the day following its publication on the Official Journal.

  • This international fusion energy project is a first-of-a kind long-term project to build and operate a reactor to test the feasibility of fusion as an energy source.
  • Decision 2007/198/Euratom established the European Joint Undertaking for ITER and the Development of Fusion Energy to provide the contribution of Euratom to the ITER International Fusion Energy Organisation and the Broader Approach Activities with Japan as well as to prepare and coordinate a programme of activities in preparation for the construction of a demonstration fusion reactor and related facilities.